Clinically, immunohistochemistry analysis is often used as an alternative method to classify breast cancer into four types (luminal A, luminal B, HER2-enriched, and triple-negative) based on the expression status of ER, PR, HER2, and Ki67 (4). This evidence concerns the gene PGR and breast cancer.